<DOC>
	<DOCNO>NCT02177344</DOCNO>
	<brief_summary>The objective study confirm chronic dose 20 mcg 40 mcg ipratropium bromide , administer via RESPIMAT device , demonstrate clinical comparability similar safety profile 36 mcg dose ATROVENT® Inhalation Aerosol ( contain chlorinate fluorocarbon ( CFC ) ) patient chronic obstructive pulmonary disease ( COPD ) . The efficacy safety profile two dos administer via RESPIMAT device also compare respective placebo group</brief_summary>
	<brief_title>Safety Efficacy Two Different Doses Ipratropium Bromide Versus ATROVENT® Inhalation Aerosol Adults With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>1 . All patient must diagnosis COPD must meet follow spirometric criterion : Patients must relatively stable , moderate severe airway obstruction FEV1 = &lt; 65 % predict normal FEV1 = &lt; 70 % FVC 2 . Male female patient 40 year age old 3 . Patients must smoke history ten packsyears . A packyear defined equivalent smoke one pack 20 cigarette per day year 4 . Patients must able perform pulmonary function test maintain record study period , require protocol 5 . Patients must able trained proper use inhalation aerosol Respimat device 6 . All patient must sign Informed Consent Form prior participation trial i.e. , least 24 hour prior screen ( Visit 1 ) 1 . Patients significant disease COPD exclude . A significant disease define disease , opinion investigator , may either put patient risk participation study disease may influence result study patient 's ability participate study 2 . Patients clinically relevant abnormal baseline haematology , blood chemistry urinalysis . If abnormality defines disease list exclusion criterion , patient exclude 3 . All patient serum glutamate oxaloacetate transaminase &gt; 80 U/L , serum glutamate pyruvate transaminase &gt; 80 U/L , bilirubin &gt; 34.2 µmol/L creatinine &gt; 176.8 µmol/L exclude regardless clinical condition . Repeat laboratory evaluation conduct subject 4 . Patients blood eosinophil count &gt; = 0.6 GI/L . A repeat eosinophil count conduct patient 5 . Patients recent history ( i.e. , one year less ) myocardial infarction 6 . Patients recent history ( i.e. , three year less ) heart failure patient cardiac arrhythmia require drug therapy 7 . Patients history cancer , treat basal cell carcinoma , within last five year 8 . Patients history lifethreatening pulmonary obstruction , history cystic fibrosis bronchiectasis 9 . Patients undergone thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion criterion # 1 10 . Patients history asthma , allergic rhinitis atopy 11 . Patients history and/or active alcohol drug abuse 12 . Patients know active tuberculosis 13 . Patients upper respiratory tract infection COPD exacerbation past six week prior Screening Visit ( Visit 1 ) baseline period 14 . Patients know symptomatic prostatic hypertrophy , bladder neck obstruction , urinary retention 15 . Patients know narrowangle glaucoma , raise intraocular pressure 16 . Patients current significant psychiatric disorder 17 . Patients regular use daytime oxygen therapy 18 . Patients treat cromolyn sodium nedocromil sodium 19 . Patients treat antihistamine 20 . Patients use oral corticosteroid medication unstable dos ( i.e. , less six week stable dose ) dose excess equivalent 10 mg prednisone per day 20 mg every day 21 . Patients treat betablocker medication 22 . Patients change therapeutic plan within last six week prior Screening Visit ( Visit 1 ) 23 . Pregnant nursing woman woman childbearing potential use medically approve mean contraception ( i.e. , oral contraceptive , intrauterine device diaphragm spermicide , Norplant® ) 24 . Patients know hypersensitivity anticholinergic drug component ATROVENT® Solution include Benzalkonium chloride Edetic acid 25 . Patients take investigational drug within one month six half life ( whichever great ) prior Screening Visit ( Visit 1 ) 26 . Previous participation study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>